226 related articles for article (PubMed ID: 26872725)
1. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Wang Y; Zhu Y; Wang Q; Hu H; Li Z; Wang D; Zhang W; Qi B; Ye J; Wu H; Jiang H; Liu L; Yang J; Cheng J
Cancer Lett; 2016 Apr; 374(1):12-21. PubMed ID: 26872725
[TBL] [Abstract][Full Text] [Related]
2. Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.
Yang CY; Lin CK; Tsao CH; Hsieh CC; Lin GJ; Ma KH; Shieh YS; Sytwu HK; Chen YW
Oncotarget; 2017 May; 8(20):33756-33769. PubMed ID: 28422711
[TBL] [Abstract][Full Text] [Related]
3. Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma.
Lin CS; Lin YC; Adebayo BO; Wu A; Chen JH; Peng YJ; Cheng MF; Lee WH; Hsiao M; Chao TY; Yeh CT
Cancer Lett; 2015 Nov; 368(1):36-45. PubMed ID: 26184998
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition.
Alhousami T; Diny M; Ali F; Shin J; Kumar G; Kumar V; Campbell JD; Noonan V; Hanna GJ; Denis GV; Monti S; Kukuruzinska MA; Varelas X; Bais MV
Mol Cancer Res; 2022 May; 20(5):712-721. PubMed ID: 35105672
[TBL] [Abstract][Full Text] [Related]
5. microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1.
Wangzhou K; Fu W; Li M; Lu Z; Lai Z; Liu C; Tan Y; Hao C
Oral Dis; 2023 Mar; 29(2):491-504. PubMed ID: 34152066
[TBL] [Abstract][Full Text] [Related]
6. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.
Fu G; Somasundaram RT; Jessa F; Srivastava G; MacMillan C; Witterick I; Walfish PG; Ralhan R
Oncotarget; 2016 Mar; 7(13):17162-81. PubMed ID: 26934445
[TBL] [Abstract][Full Text] [Related]
7. SOX4 expression is associated with treatment failure and chemoradioresistance in oral squamous cell carcinoma.
Yoon TM; Kim SA; Cho WS; Lee DH; Lee JK; Park YL; Lee KH; Lee JH; Kweon SS; Chung IJ; Lim SC; Joo YE
BMC Cancer; 2015 Nov; 15():888. PubMed ID: 26555193
[TBL] [Abstract][Full Text] [Related]
8. Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1.
Zhang W; Cheng J; Diao P; Wang D; Zhang W; Jiang H; Wang Y
Br J Cancer; 2020 Feb; 122(4):528-538. PubMed ID: 31848446
[TBL] [Abstract][Full Text] [Related]
9. Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma.
Benhamou Y; Picco V; Raybaud H; Sudaka A; Chamorey E; Brolih S; Monteverde M; Merlano M; Lo Nigro C; Ambrosetti D; Pagès G
Oncotarget; 2016 Jul; 7(28):44236-44251. PubMed ID: 27329590
[TBL] [Abstract][Full Text] [Related]
10. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
He Y; Zhao Y; Wang L; Bohrer LR; Pan Y; Wang L; Huang H
Oncogene; 2018 Jan; 37(4):534-543. PubMed ID: 28991226
[TBL] [Abstract][Full Text] [Related]
11. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells.
Lee JC; Chung LC; Chen YJ; Feng TH; Chen WT; Juang HH
Cancer Lett; 2015 May; 360(2):310-8. PubMed ID: 25721086
[TBL] [Abstract][Full Text] [Related]
13. Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells.
Hoshino I; Akutsu Y; Murakami K; Akanuma N; Isozaki Y; Maruyama T; Toyozumi T; Matsumoto Y; Suito H; Takahashi M; Sekino N; Komatsu A; Suzuki T; Matsubara H
Ann Surg Oncol; 2016 Jan; 23(1):312-20. PubMed ID: 25791791
[TBL] [Abstract][Full Text] [Related]
14. High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer.
Yuan C; Li Z; Qi B; Zhang W; Cheng J; Wang Y
J Oral Pathol Med; 2015 Feb; 44(2):159-65. PubMed ID: 25040359
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Yang CY; Tsao CH; Hsieh CC; Lin CK; Lin CS; Li YH; Chang WC; Cheng JC; Lin GJ; Sytwu HK; Wang YL; Chen YW
PLoS One; 2020; 15(7):e0236101. PubMed ID: 32678829
[TBL] [Abstract][Full Text] [Related]
16. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
Lu M; Wang C; Chen W; Mao C; Wang J
DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
[TBL] [Abstract][Full Text] [Related]
18. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
20. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY
Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
